Table 2.
Characteristics of patients undergoing ASCT in PET-negative CR1 a
| All (n = 105) | maintenance rituximab (n = 58) |
No-maintenance rituximab (n = 47) |
P-valueb | |
|---|---|---|---|---|
|
|
||||
| Median age at diagnosis, years (range) | 58 (35–74) | 56 (35–70) | 60 (43–74) | 0.054 |
| Male | 73 (70%) | 36 (62%) | 37 (79%) | 0.065 |
| Year of Diagnosis: 2006 and later | 81 (77%) | 48 (83%) | 33 (70%) | 0.13 |
| Stage, at diagnosis | ||||
| I/II | 3 (3%) | 1 (2%) | 2 (4%) | 0.51 |
| III | 7 (7%) | 5 (9%) | 2 (4%) | |
| IV | 95 (90%) | 52 (90%) | 43 (91%) | |
| B symptoms, at diagnosis | 16 (15%) | 6 (10%) | 10 (21%) | 0.12 |
| Bone marrow involvement, at diagnosis | 85 (81%) | 46 (79%) | 39 (83%) | 0.63 |
| Extranodal involvement, at diagnosis | 39 (37%) | 23 (40%) | 16 (34%) | 0.55 |
| Blastoid variant | 8 (8%) | 5 (9%) | 3 (6%) | 0.67 |
| MIPI | 0.36 | |||
| Low | 42 (40%) | 26 (45%) | 16 (34%) | |
| Intermediate/high | 33 (31%) | 15 (26%) | 18 (38%) | |
| Unknown | 30 (29%) | 17 (29%) | 13 (28%) | |
| High-dose cytarabine pre-ASCT | 64 (61%) | 43 (74%) | 21 (45%) | 0.002 |
| Rituximab pre-ASCT | 104 (99%) | 57 (98%) | 47 (100%) | 1.0 |
| Median time from dx to ASCT (months) | 7.4 (4.8–105.3) | 7.0 (4.8–105.3) | 8.0 (4.9–20.7) | 0.052 |
| Year of ASCT, 2007 and later | 81 (77%) | 48 (83%) | 33 (70%) | 0.13 |
| No of regimens pre-ASCT, 2 or 3 | 18 (17%) | 11 (19%) | 7 (15%) | 0.58 |
| Radiation-based conditioning | 46 (44%) | 24(41%) | 22 (47%) | 0.58 |
| Median followup post-ASCT, yrs. (range)c | 5.5 (2.1–13.0) | 5.9 (2.1–12.3) | 5.2 (2.1–13.0) | 0.20 |
| Median time from ASCT to maintenance rituximab (days) | n/a | 129 (36–451) | n/a | |
Abbreviations: CR, complete remission; ASCT, high-dose therapy; MIPI, mantle cell lymphoma International prognostic index; maintenance rituximab, maintenance rituximab.
a
PET scans were available for 133 patients, 105 of whom were in CR1 prior to transplant.
b
P-values comparing the maintenance rituximab and no-maintenance rituximab groups.